2025 International MSA Congress
Cutaneous Phosphorylated Alpha-Synuclein Deposition Increases Over Time and Informs Function in Individuals with Early-Stage Multiple System Atrophy
The MSA Atrophy Index (MSA-AI): Quantitative Imaging Marker for the Diagnosis and Monitoring of Multiple System Atrophy
A Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in MSA
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Alterity Therapeutics a question about this update.